TUKYSA (tucatinib) tablets, for oral use Initial U.S. Approval: 2020

Category: .

TUKYSA (tucatinib) tablets, for oral use Initial U.S. Approval: 2020

INDICATIONS AND USAGE
TUKYSA is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
DOSAGE FORMS & STRENGTHS
Tablets: 50 mg and 150 mg
Manufactured By: Seattle Genetics
Prescribing Information URL: Click Here

Access to TUKYSA ™ (tucatinib) tablets: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Tucatinib (INN), sold under the brand name Tukysa, is a small molecule inhibitor of HER2 for the treatment of HER2-positive breast cancer. It was developed by Array BioPharma and licensed to Cascadian Therapeutics (formerly Oncothyreon, subsequently part of Seattle Genetics).
Tucatinib was approved for medical use in Australia in August 2020.
Tucatinib is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.